BioCentury
ARTICLE | Company News

Diagnostic companies Cancer Genetics, NovellusDx merging

September 21, 2018 4:36 PM UTC

Cancer diagnostic company Cancer Genetics Inc. (NASDAQ:CGIX) will merge with NovellusDx Ltd. (Jerusalem, Israel). NovellusDx shareholders will have a 49% equity stake in the company, which will retain Cancer Genetics’ name.

NovellusDx’s assays distinguish passenger and driver mutations in patients’ tumors to help physicians prioritize treatment options. Cancer Genetics CEO John Roberts will be the combined company’s CEO. NovellusDx Chairman Charles Woler will serve as the newco’s chairman (see "Signal Mapping")...